Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.

Abstract

Olanzapine, an atypical antipsychotic drug, was administered to a patient with Huntington's disease (HD) with marked choreiform movements. Brain SPECT with 99mTc-HMPAO was performed before and after treatment. Brain SPECT imaging has been performed in patients with HD in order to determine the status of basal ganglia perfusion. The use of brain SPECT with 99mTc-HMPAO before and after treatment in patients with HD has not been yet reported. The marked hypoperfusion of the basal ganglia on brain SPECT performed before therapy with olanzapine improved significantly after treatment.

• Authors: E C Etchebehere, M C Lima, W Passos, J A Maciel Júnior, A O Santos, C D Ramos, E E Camargo
• Journal: Arquivos de neuro-psiquiatria (Arq Neuropsiquiatr) Vol. 57 Issue 3B Pg. 863-6 (Sep 1999) ISSN: 0004-282X [Print] Germany
• PMID: 10751925 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antipsychotic Agents
• Radiopharmaceuticals
• Benzodiazepines
• Technetium Tc 99m Exametazime
• Pirenzepine
• Olanzapine

Topics

• Adult
• Antipsychotic Agents (therapeutic use)
• Benzodiazepines
• Brain (diagnostic imaging)
• Female
• Humans
• Huntington Disease (diagnostic imaging, drug therapy)
• Olanzapine
• Pirenzepine (analogs & derivatives, therapeutic use)
• Radiopharmaceuticals
• Technetium Tc 99m Exametazime
• Tomography, Emission-Computed, Single-Photon